Subscribe to Search results

In an information sheet about AIDS it was stated that the DHSS Medicines and Supply Divisions were endeavouring to ensure that there would be no "dumping" of high-risk plasma products on the UK market.

Published on:

A letter from Lord Glenarthur contemplated that future blood product supplies for the UK would not all be manufactured from pre-March 1983 plasma.

Published on:

C Wrigglesworth requested Dr Walford's views on whether any action was required in relation to the stocks of pre-March 1983 material and suggested there was a conflict between the result of the FDA meeting and the 13 July CSM(B) recommendation.

Published on:

In a memo, Dr Walford stated Dr Smith had "carefully worded [the] recommendation" of the CSM paper and "that supply of material must take precedence over [the] implementation [of CSM(B)'s recommendation]."

Published on:

An internal Armour memo suggested it was "vitally important" that Armour sell the products manufactured from plasma collected prior to the March 1983 FDA memorandum as quickly as possible.

Published on:

Christopher Bishop stated in his oral evidence that Armour had no qualms internally about disposing of or selling pre-March 1983 product in the UK.

Published on:

In a memo to Dr Walford, Mr Wrigglesworth (DHSS) queried whether further action was required on pre-March 1983 blood products as such products continued to be used in the USA.

Published on:

Lord Glenarthur wrote to Clive Jenkins, stating "there is no conclusive evidence that AIDS is transmitted through blood products. Nevertheless we are taking all practicable measures to reduce any possible risks to recipients of blood and blood products".

Published on:

MRC issued a brief on AIDS stating that, "over the last six months the possibility of transmission by blood transfusion has become increasingly apparent".

Published on:

The DHSS contemplated accompanying a leaflet advising high risk groups against donation in the UK, with an explanation that the US FDA had introduced requirements for plasma collection which were designed to exclude donors from high-risk groups.

Published on:

Lord Glenarthur approved a letter which stated that "in the absence of any screening test for AIDS we must ensure that all donations are, as far as possible, free from the possibility of infection."

Published on:

The Sub-Committee on Safety of Medicines (biological) recommended not licensing the Tisseel Kit, a blood product produced by Immuno.

Published on:

Hyland/Travenol learned of Behringwerke's product which was treated to eliminate the risk of hepatitis.

Published on:

Hyland Inter-office memo regarding being aware of the fact that Behring were in the last stages of clinical trials of "hepatitis risk-free" AHF.

Published on:

Hyland Inter-Office memo attaching a booklet regarding AHF improvements.

Published on:

Travenol Laboratories Ltd submitted a product licence application for Hemofil-T.

Published on:

Hoechst UK limited applied for a product licence for what would later be known as Haemate P.

Published on:

Armour submitted a product licence application for Heat Treated High Potency Factorate.

Published on:

In February 1985 the heat treated products of Baxter, Alpha, Armour, Cutter and Immuno were all licensed.

Published on:

CSM(B) was unable to recommend a product licence for Hemofil-T.

Published on: